As Interim Education Director, Dr. Mobley coordinates the psychiatry curriculum between the six regional FSUCOM campuses and the main campus. As clerkship director, he plans and manages the psychiatry curriculum and training of third- and fourth-year medical students at the Pensacola Regional Medical School Campus. He serves as psychosocial facilitator for the Doctoring 3 course on the Pensacola campus. He is a Clinical Professor in the Department of Clinical Sciences.
Dr. Mobley is the Escambia County Florida Jail psychiatrist and has been since 2008. He has consulting staff privileges at Lakeview Center, which is the local community mental health center. In addition to his position at the jail and his positions with the College of Medicine, he serves as the Medical Director of Access Behavioral Health (the managing entity for the Medicaid prepaid mental health plan in Northwest Florida). He was in the private practice of psychiatry in Pensacola from 1987 until 2008.
B.S., Arkansas State University, 1974
M.D., University of Arkansas, 1979
Internship, University Hospital, 1979-1980
Psychiatry Residency, Arkansas State Hospital, 1980-1983
He is a Diplomate of the American Board of Psychiatry and Neurology.
Dr. Mobley currently serves on two statewide committees. He is a member of Florida's Agency for Healthcare Administration Drug Utilization Review Board and the Expert Colloquium, which is sponsored by the Louis de la Parte Institute (Florida Mental Health Institute) at the University of South Florida. Membership in these two groups allows input into one of his special interests: The quest for the continuous improvement of care of the chronically mentally ill in the State of Florida. He served as President of Baptist Hospital's Medical Staff in 2002.
Clerkship Director of the Year (Pensacola Campus) 2006
Education Director of the Year (FSU College of Medicine) 2006
Distinguished Service Award to the College of Medicine 2006
Fellow of the American Psychiatric Association
Florida Psychiatric Society
Alpha Omega Alpha
Polypharmacy versuses monotherapy using antipsychotics while treating schizophrenia and schizoaffective disorder among the chronically and persistently mentally ill.